RxDoctor Payments Data

Gurdeep Kundlas, MD

Family Medicine · Bath, NYNPI 1063477677

Payments from drug & device makers

$822in general payments, 2019–2025

Across 46 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$210
  • AstraZeneca$156
  • Boehringer Ingelheim$87
  • Novartis$80
  • Kowa Pharmaceuticals America, Inc.$68
  • Johnson & Johnson$55
  • plus $166 from 6 others

What the payments were for

  • Food & beverage$81199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$822 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$122,594
Medicare patients
399
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$120,379
EliquisApixaban146$119,746
JanuviaSitagliptin Phosphate117$96,784
TrulicityDulaglutide69$88,598
XareltoRivaroxaban70$81,006
JardianceEmpagliflozin50$51,026
FarxigaDapagliflozin Propanediol41$34,451
Breo ElliptaFluticasone/Vilanterol38$17,031
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$14,161
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$13,709
Combivent RespimatIpratropium/Albuterol Sulfate11$12,153
Repatha SyringeEvolocumab14$10,366
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$10,225
SymbicortBudesonide/Formoterol Fumarate21$7,358
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$29$125,092161 claims
Novo NordiskOzempic$210$120,37980 claims
MerckJanuvia$32$96,784117 claims
Lilly USA, LLCTrulicity$37$88,59869 claims
Johnson & JohnsonXarelto$55$81,00670 claims
Boehringer IngelheimJardiance, Combivent Respimat$87$63,17961 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$156$55,51878 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bath

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →